[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201891478A1 - Способы и композиции для оценки риска возникновения рака - Google Patents

Способы и композиции для оценки риска возникновения рака

Info

Publication number
EA201891478A1
EA201891478A1 EA201891478A EA201891478A EA201891478A1 EA 201891478 A1 EA201891478 A1 EA 201891478A1 EA 201891478 A EA201891478 A EA 201891478A EA 201891478 A EA201891478 A EA 201891478A EA 201891478 A1 EA201891478 A1 EA 201891478A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
compositions
methods
risk assessment
risk
Prior art date
Application number
EA201891478A
Other languages
English (en)
Inventor
Жан-Франсуа Флош
Original Assignee
Синсерю С.А Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синсерю С.А Р.Л. filed Critical Синсерю С.А Р.Л.
Publication of EA201891478A1 publication Critical patent/EA201891478A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение предлагает способ оценки риска возникновения рака у индивида.
EA201891478A 2015-12-31 2017-01-02 Способы и композиции для оценки риска возникновения рака EA201891478A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307190 2015-12-31
EP16305133 2016-02-05
PCT/EP2017/050034 WO2017114973A1 (en) 2015-12-31 2017-01-02 Compositions and methods for assessing the risk of cancer occurrence

Publications (1)

Publication Number Publication Date
EA201891478A1 true EA201891478A1 (ru) 2019-01-31

Family

ID=57821944

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891478A EA201891478A1 (ru) 2015-12-31 2017-01-02 Способы и композиции для оценки риска возникновения рака

Country Status (17)

Country Link
US (2) US11085924B2 (ru)
EP (1) EP3397965B1 (ru)
JP (1) JP6940505B2 (ru)
KR (1) KR102620651B1 (ru)
CN (2) CN114705858A (ru)
AU (1) AU2017204683B2 (ru)
BR (1) BR112018013269A2 (ru)
CA (1) CA3009768A1 (ru)
CL (1) CL2018001788A1 (ru)
CO (1) CO2018007621A2 (ru)
EA (1) EA201891478A1 (ru)
IL (1) IL260301A (ru)
MA (1) MA43550A (ru)
MX (1) MX2018008175A (ru)
SG (1) SG11201804629XA (ru)
TN (1) TN2018000197A1 (ru)
WO (1) WO2017114973A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017114973A1 (en) * 2015-12-31 2017-07-06 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence
CN110662769B (zh) * 2017-03-30 2023-10-20 普莱戈斯瑞恩癌症有限责任公司 使用前胃泌素结合分子检测和治疗前列腺癌的组合物和方法
SG11201908888VA (en) 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for treating lung cancer
CN112004560A (zh) * 2017-12-08 2020-11-27 Ecs生物识别系统有限公司 癌症诊断中的放射性标记的前胃液素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
WO2019166499A1 (en) * 2018-02-27 2019-09-06 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
PT970126E (pt) 1997-04-14 2001-10-30 Micromet Ag Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2580965C (en) * 2004-09-22 2014-04-08 Receptor Biologix, Inc. Monoclonal antibodies to progastrin
CN101368966A (zh) * 2008-04-29 2009-02-18 北京科美东雅生物技术有限公司 一种胃泌素释放肽前体化学发光免疫分析测定试剂盒
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
AU2014203017B2 (en) * 2009-10-16 2017-02-02 Centre National De La Recherche Scientifique (Cnrs) Monoclonal antibodies to progastrin and their uses
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
KR101570404B1 (ko) 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 결장직장암 및 위창자암의 예방
PL2598531T3 (pl) 2010-07-26 2021-08-30 Progastrine Et Cancers S.À R.L. Sposoby i kompozycje do terapii nowotworu wątroby
EP2715364A1 (en) * 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
WO2017114973A1 (en) * 2015-12-31 2017-07-06 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence

Also Published As

Publication number Publication date
IL260301A (en) 2018-08-30
US11085924B2 (en) 2021-08-10
EP3397965A1 (en) 2018-11-07
AU2017204683B2 (en) 2023-03-16
US20190011452A1 (en) 2019-01-10
TN2018000197A1 (en) 2019-10-04
MA43550A (fr) 2018-11-07
CA3009768A1 (en) 2017-07-06
MX2018008175A (es) 2019-02-20
CN114705858A (zh) 2022-07-05
JP6940505B2 (ja) 2021-09-29
KR20180093973A (ko) 2018-08-22
WO2017114973A1 (en) 2017-07-06
BR112018013269A2 (pt) 2018-12-11
EP3397965B1 (en) 2024-09-11
CN108700586B (zh) 2024-08-23
CN108700586A (zh) 2018-10-23
CO2018007621A2 (es) 2018-10-22
JP2019505783A (ja) 2019-02-28
KR102620651B1 (ko) 2024-01-04
CL2018001788A1 (es) 2018-09-21
US20210373027A1 (en) 2021-12-02
AU2017204683A1 (en) 2018-06-21
SG11201804629XA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
ZA202107931B (en) Anti-tau antibodies and methods of use
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
DK3125927T3 (da) Fremgangsmåder og sammensætninger til immunmodulering
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
DK3316909T5 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3430038T3 (da) Sammensætninger og fremgangsmåder til cd20-immunterapi
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3324932T3 (da) Sammensætninger og fremgangsmåder for nanopartikel lyofile former
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
MX2016006165A (es) Composiciones y metodos para valorar la funcion intestinal.
EA201791538A1 (ru) Способ предотвращения или лечения потери слуха
PH12017501864A1 (en) Compositions and methods for treating autism
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
DK3244166T3 (da) System og fremgangsmåde til at identificere socialt relevante landmærker
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
TR201909125T4 (tr) Yüzey temi̇zlemek i̇çi̇n bi̇r aparat